Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue ...
Hosted on MSN
Gilead’s new HIV prevention drug lenacapavir will ‘change the face of HIV,’ says CEO Daniel O’Day
Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and chief executive Daniel O’Day. He dubbed lenacapavir – the company’s twice-a ...
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among ...
(Reuters) -Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy ...
News Is Out hosts an online panel discussion with Gilead’s Choose U ambassadors sharing stories of resilience, empowerment ...
The Food and Drug Administration on Wednesday approved Gilead's twice-yearly antiviral injection for preventing HIV — a milestone that the company and some experts say could help bring the world ...
– The Novel HIV Therapy has the Potential to Expand Options for Virologically Suppressed Adults Treated with Complex ART Regimens – – Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis ...
Irish Examiner on MSN
Gilead profits rise to €631m driven by 9% jump in turnover
Gilead mainly produces drugs to combat HIV and Hepatitis C, while its Veklury medicine is a treatment for covid-19.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback